Phase 2 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults of any gender may be considered for this trial
- People who have been diagnosed with liver cancer (hepatocellular carcinoma) at a specific stage of progression known as BCLC stage B or C
- People whose cancer cells test positive for a specific protein marker called hTERT, confirmed through screening tests
- People whose general health and ability to carry out daily activities falls within a certain range, measured by a standard medical scoring system called the ECOG scale (score of 0 or 1, meaning fully active or restricted in strenuous activity only)
- People whose liver function falls within a certain healthy range, measured by a scoring system called Child-Pugh (score of A, meaning relatively well-functioning liver)
- People who are expected to live for at least 3 months or longer
Who may not be able to join:
- People who have moderate or severe fluid build-up in the abdomen (ascites)
- People who have previously experienced, or currently have, a condition where the liver is unable to remove toxins from the blood, causing brain function problems (hepatic encephalopathy)
- People who have another type of cancer in addition to liver cancer
- People who currently have, or have previously tested positive for, HIV
- People who the trial doctor determines are not suitable for the trial for any other reason (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +82-31-706-8730
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with adverse events (AEs) as graded by NCI CTCAE; Assessment of tumor response of target lesion where RZ-001 is administered based on the RECIST v1.1 and HCC mRECIST; Overall response rate based on RECIST v1.1 and HCC mRECIST
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.